FOLH1 and posterior cortical atrophy: Thus, as recently stated by the EAU consensus panel in advanced PCa [16], ASCO guidelines [15], and Advanced PCa Consensus Conference (APCC) [9], it should also be recognized that the majority of patients in clinical trials who benefited from the addition of next-generation ADT would probably have had positive PSMA-PET imaging results.